Carline Groenland

Dr. Carline Groenland

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in Critical Care Medicine
Verified
Journal Article
Open access
MHMichael C. van Herwerden
Michael C. van Herwerden
CGCarline Groenland
Carline Groenland
FTFabian Termorshuizen
Fabian Termorshuizen
WRWim J. R. Rietdijk
Wim J. R. Rietdijk
FBFredrike Blokzijl
Fredrike Blokzijl
CUCorstiaan A. Den Uil
Corstiaan A. Den Uil
OBJECTIVES: This study aimed to provide new insights into the impact of emergency department (ED) to ICU time on hospital mortality, stratifying patients by academic and nonacademic teaching (NACT) hospitals, and considering Acute Physiology and Chronic Health Evaluation (APACHE)-IV probability and ED-triage scores. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective cohort study (2009–2020) using data from the Dutch National Intensive Care Evaluation registry. Patients directly admitted from the ED to the ICU were included from four academic and eight NACT hospitals. Odds ratios (ORs) for mortality associated with ED-to-ICU time were estimated using multivariable regression, both crude and after adjusting for and stratifying by APACHE-IV probability and ED-triage scores. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 28,455 patients were included. The median ED-to-ICU time was 1.9 hours (interquartile range, 1.2–3.1 hr). No overall association was observed between ED-to-ICU time and hospital mortality after adjusting for APACHE-IV probability (p = 0.36). For patients with an APACHE-IV probability greater than 55.4% (highest quintile) and an ED-to-ICU time greater than 3.4 hours the adjusted OR (ORsadjApache) was 1.24 (95% CI, 1.00–1.54; p < 0.05) as compared with the reference category (< 1.1 hr). In the academic hospitals, the ORsadjApache for ED-to-ICU times of 1.6–2.3, 2.3–3.4, and greater than 3.4 hours were 1.21 (1.01–1.46), 1.21 (1.00–1.46), and 1.34 (1.10–1.64), respectively. In NACT hospitals, no association was observed (p = 0.07). Subsequently, ORs were adjusted for ED-triage score (ORsadjED). In the academic hospitals the ORsadjED for ED-to-ICU times greater than 3.4 hours was 0.98 (0.81–1.19), no overall association was observed (p = 0.08). In NACT hospitals, all time-ascending quintiles had ORsadjED values of less than 1.0 (p < 0.01). CONCLUSIONS: In patients with the highest APACHE-IV probability at academic hospitals, a prolonged ED-to-ICU time was associated with increased hospital mortality. We found no significant or consistent unfavorable association in lower APACHE-IV probability groups and NACT hospitals. The association between longer ED-to-ICU time and higher mortality was not found after adjustment and stratification for ED-triage score.

8 January 2025 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
CGCarline Groenland
Carline Groenland
ASAdinde H. Siemers
Adinde H. Siemers
EDEric A. Dubois
Eric A. Dubois
DGDiederik Gommers
Diederik Gommers
LHLeo Heunks
Leo Heunks
HEHenrik Endeman
Henrik Endeman
Extubation failure is associated with an increased morbidity, emphasizing the need to identify factors to further optimize extubation practices. The role of biomarkers in the prediction of extubation failure is currently limited. The aim of this study was to investigate the prognostic value of cardiac (N-terminal pro–B-type natriuretic peptide (NT-proBNP), High-sensitivity Troponin T (Hs-TnT)) and inflammatory biomarkers (Interleukin-6 (IL-6) and Procalcitonin (PCT)) for extubation failure in patients with COVID-19 Acute Respiratory Distress Syndrome (C-ARDS). In this single-center retrospective cohort study, patient characteristics and laboratory measurements were extracted from electronic medical records. Patients were eligible for inclusion if they were extubated after mechanical ventilation. The primary endpoint was extubation failure, defined as the need for reintubation or death within the next seven days after extubation, regardless of whether post-extubation respiratory support was used. Uni- and multivariable logistic regression was performed to investigate the association between biomarkers and extubation failure. Biomarkers were log2 transformed. Of the 297 patients included, 21.5% experienced extubation failure. In univariable analysis, NT-proBNP (OR 1.24, 95% CI 1.06–1.47), Hs-TnT (OR 1.72, 95% CI 1.37–2.19) and PCT (OR 1.38, 95% CI 1.16–1.65) measured on the day of extubation were significantly associated with extubation failure. After multivariable adjustment for clinical variables (age, duration of mechanical ventilation, SOFA score), Hs-TnT was the only biomarker that was independently associated with extubation failure (adjusted OR 1.38, 95% CI 1.02–1.90). Patients with both elevated Hs-TnT (≥ 14 ng/mL) and elevated PCT (≥ 0.25 ng/mL) carried the highest risk of extubation failure (46%), while in patients with normal Hs-TnT and PCT values, only 13% experienced extubation failure. Hs-TnT, NT-proBNP and PCT measured on the day of extubation are associated with extubation failure in mechanically ventilated patients with C-ARDS. Since Hs-TnT is the only biomarker that is independently associated with extubation failure, Hs-TnT could offer additional objective measures for assessing readiness for extubation. Future studies should focus on an integrative approach of biomarkers combined with relevant clinical factors to predict extubation failure.

Verified
Journal Article
Open access
PDF file
CGCarline Groenland
Carline Groenland
MBMaud A. Blijleven
Maud A. Blijleven
IRImane Ramzi
Imane Ramzi
EDEric A Dubois
Eric A Dubois
LHLeo Heunks
Leo Heunks
VBVivan J. M. Baggen
Vivan J. M. Baggen
Background: It is unclear whether other cardiac biomarkers than NT-proBNP can be useful in the risk stratification of patients weaning from mechanical ventilation. The aim of this study is to summarize the role of ischemic cardiac biomarkers in predicting spontaneous breathing trial (SBT) or extubation failure. Methods: We systematically searched Embase, MEDLINE, Web of Science, and Cochrane Central for studies published before January 2024 that reported the association between ischemic cardiac biomarkers and SBT or extubation failure. Data were extracted using a standardized form and methodological assessment was performed using the QUIPS tool. Results: Seven observational studies investigating four ischemic cardiac biomarkers (Troponin-T, Troponin-I, CK-MB, Myoglobin) were included. One study reported a higher peak Troponin-I in patients with extubation failure compared to extubation success (50 ng/L [IQR, 20–215] versus 30 ng/L [IQR, 10–86], p = 0.01). A second study found that Troponin-I measured before the SBT was higher in patients with SBT failure in comparison to patients with SBT success (100 ± 80 ng/L versus 70 ± 130 ng/L, p = 0.03). A third study reported a higher CK-MB measured at the end of the SBT in patients with weaning failure (SBT or extubation failure) in comparison to weaning success (8.77 ± 20.5 ng/mL versus 1.52 ± 1.42 ng/mL, p = 0.047). Troponin-T and Myoglobin as well as Troponin-I and CK-MB measured at other time points were not found to be related to SBT or extubation failure. However, most studies were underpowered and with high risk of bias. Conclusions: The association with SBT or extubation failure is limited for Troponin-I and CK-MB and appears absent for Troponin-T and Myoglobin, but available studies are hampered by significant methodological drawbacks. To more definitively determine the role of ischemic cardiac biomarkers, future studies should prioritize larger sample sizes, including patients at risk of cardiac disease, using stringent SBTs and structured timing of laboratory measurements before and after SBT.

12 November 2025 in Biomarker Insights
Verified
Journal Article
Open access
CGCarline Groenland
Carline Groenland
ASAdinde H. Siemers
Adinde H. Siemers
EDEric A. Dubois
Eric A. Dubois
DGDiederik Gommers
Diederik Gommers
LHLeo Heunks
Leo Heunks
HEHenrik Endeman
Henrik Endeman
Background: Extubation failure is associated with adverse outcomes in critically ill patients. While single biomarker measurements can aid prediction, repeated biomarker measurements can help to timely recognize underlying diseases. Objectives: The aim of this study was to investigate the temporal evolution of cardiac (N-terminal pro–B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T [Hs-TnT]) and inflammatory biomarkers (interleukin-6 [IL-6] and procalcitonin [PCT]) prior to extubation and determine their additional prognostic value. Design: Retrospective cohort study. Methods: Patients with COVID-19 extubated after mechanical ventilation were included. Daily biomarker levels were collected up to 3 days before extubation. The primary endpoint was extubation failure, defined as reintubation or death within 7 days. Linear mixed-effect models were used to analyze biomarker trajectories in patients with extubation success and failure. Each day before extubation a logistic regression model (consisting of the 4 biomarkers) was constructed to determine the model with the best discriminative ability. Results: Among 297 patients, 21.5% experienced extubation failure. Log 2 Hs-TnT, NT-proBNP and PCT were higher on all days in patients with extubation failure ( P < .001, P = .01, P = .01, respectively), whereas log 2 IL-6 was not ( P = .54). There was no difference in the change of biomarkers over the days between patients with extubation success and failure ( P -value for interaction = .11, P = .82, P = .31, P = .84, respectively). The performance of the logistic regression model including the 4 biomarkers on the day of extubation was significantly better than the model 3 days before extubation (AUC 0.71, 95% CI: 0.64-0.79 vs AUC 0.66, 95% CI: 0.58-0.73, P = .03). Conclusion: Hs-TnT, NT-proBNP and PCT measured on the days before extubation are consistently higher in patients with extubation failure. However, there was no relation between the change in biomarker levels over time and extubation outcome. The serial assessment of Hs-TnT, NT-proBNP, PCT, and IL-6 do not seem to add prognostic information to predict extubation failure.

12 February 2026
Verified
Conference Paper
Closed access
CGCarline Groenland
Carline Groenland
EWEvert-Jan Wils
Evert-Jan Wils
EDEric Dubois
Eric Dubois
EBEdske Ter Bals
Edske Ter Bals
TRThijs Rettig
Thijs Rettig
VBVivan Baggen
Vivan Baggen
Introduction Extubation failure occurs in up to 20%, despite a successful spontaneous breathing trial (SBT). We hypothesized that serial biomarkers during an SBT could identify patients at risk. We aimed to investigate the association between serial biomarkers during an SBT and extubation failure. Methods We included adult patients ventilated ≥48 hours and undergoing an SBT in a multicenter cohort study. Primary and secondary endpoints were extubation failure (reintubation ≤7-days), and ICU mortality. Logistic regression assessed associations between log2-transformed biomarkers at SBT start and their relative change during the SBT with the endpoints. Post-hoc analyses focused on extubation failure due to non-airway failure (exclusion of extubation failure due to airway problems). Results 150 patients were included (mean age 63±13 years, 61% male). None of the biomarkers (start SBT and relative change (not presented)) were associated with extubation failure (n=33, 22%, Figure 1). However, Hs-Troponin-T (Hs-TnT), CKMB, Cystatin-C measured at start of the SBT were associated with extubation failure due to non-airway failure (n=23), and NT-proBNP, Hs-TnT, Galectin-3, and Cystatin-C with ICU mortality. Conclusions Although biomarkers were not associated with extubation failure, we found associations of cardiac and renal biomarkers with non-airway failure (Hs-TnT, CKMB, Cystatin-C) and ICU mortality (NT-proBNP, Hs-TnT, Galectin-3, Cystatin-C). erjor;12/suppl_17/135/F1 F1 F1